List view / Grid view

Debiopharm International SA



Debiopharm’s triptorelin 6-month formulation receives EU approval

20 March 2017 | By Niamh Marriott, Junior Editor

Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in 22 European countries, where the 6-month formulation has already been registered for the treatment of prostate cancer. Triptorelin is the…